An Observational Prospective Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Shire4 sites in 3 countries19 target enrollmentApril 9, 2012

ConditionsSanfilippo Syndrome Type B

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sanfilippo Syndrome Type B
Sponsor: Shire
Enrollment: 19
Locations: 4
Primary Endpoint: evaluate the course of disease progression in patients with MPS IIIB who are untreated with any investigational products to inform possible future treatment studies
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the natural course of disease progression in Mucopolysaccharidosis Type III (MPS IIIB) patients who are untreated to identify potential surrogate endpoints that may be utilized in future treatment trials of MPS IIIB using predefined assessments including standardized clinical, biochemical, neurocognitive, developmental, and imaging measures.

Detailed Description

This is a multicenter longitudinal, prospective, natural history study of patients with MPSIIIB designed to identify potential surrogate endpoints that may be utilized in future Enzyme replacement therapy (ERT) trials of MPS IIIB via defined assessments including standardized clinical, biochemical, neurocognitive, development, and imaging measures.

Registry

clinicaltrials.gov

Start Date

April 9, 2012

End Date

October 10, 2013

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shire

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Each patient must meet all of the following criteria to be enrolled in this study.
•Definitive diagnosis of MPS IIIB, as determined by one of the following:
•Documented deficiency in alpha-N-acetylglucosaminidase (NAGLU) enzyme activity of ≤10% of the lower limit of the normal range as measured in fibroblasts, leukocytes, plasma, or serum (based on normal range for diagnosis of MPS IIIB). Patients who do not already have a documented deficiency of NAGLU activity will provide a blood sample during screening for determination of NAGLU activity level in their serum. OR
•Two documented mutations in the NAGLU gene. Patients who do not already have a documented genotype of NAGLU will provide a blood sample during screening for NAGLU genotyping.
•The patient is ≥1 and \< 10 years of age and has an age equivalent on the Vineland Adaptive Behavior Scales (VABS) of ≥1 year
•The patient is medically stable, in the opinion of the Investigator, to accommodate the protocol requirements, including travel and assessments, without placing an undue burden on the patient/patient's family.
•The patient, patient's parent(s) or legal guardian(s) has voluntarily signed and dated an Institutional Review Board/Independent Ethics Committee-approved informed consent (assent if applicable) form after all relevant aspects of the study have been explained and discussed with the patient, the patient's parent(s), or legal guardian(s).

Exclusion Criteria

•Patients will be excluded from the study if they meet any of the following criteria at screening:
•Presence of significant non-MPS IIIB related central nervous system (CNS) impairment or behavioral disturbances, sufficient, in the opinion of the Investigator, to preclude performance of study neurocognitive and developmental testing procedures, or that would confound the scientific integrity or interpretation of study assessments.
•Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing.
•Patient has a known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptable risk from anesthesia, due to airway compromise or other conditions, in the opinion of the Investigator.
•Personal history or family history of neuroleptic malignant syndrome, malignant hyperthermia, or other anesthesia-related concerns.
•History of poorly controlled seizure disorder.
•Currently receiving psychotropic or other medications, which in the Investigator's opinion would be likely to substantially confound test results.
•History of bleeding disorder, inability to abstain from medications that affect blood clotting(e.g., aspirin, Non-steroidal anti-inflammatory drug (NSAIDs)), or history of their ingestion within 1 week prior to a lumbar puncture.
•History of complications from previous lumbar punctures that, in the opinion of the Investigator, place the patient at increased risk from this procedure.
•The patient is participating, plans to participate, or participated in a clinical trial of another investigational medicinal product, or has received a vaccination, within the 30 days prior to the study or for less than 5 half lives (whichever is longer) of the investigational product.

Outcomes

Primary Outcomes

evaluate the course of disease progression in patients with MPS IIIB who are untreated with any investigational products to inform possible future treatment studies

Time Frame: 13 months